
Lars L. Lannfelt
Uppsala Science Park
Uppsala, C 75185, Sweden
Uppsala, C 75185, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 132 publications
Lecanemab promotes Fc receptor-dependent cell-mediated internalization and degradation of aggregated amyloid-beta in vitro and ex vivo.
Journal: Neuroscience letters
Published: February 18, 2026
MALDI mass spectrometry imaging (MSI) reveals molecular and structural heterogeneity of amyloid-β in sporadic Alzheimer's disease and Down syndrome.
Journal: Acta neuropathologica communications
Published: December 08, 2025
The Uppsala APP Mutation Promotes Wild-Type Amyloid-β Aggregation and Deposition In Vivo.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: July 28, 2025
Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: June 30, 2025
Endogenously generated Dutch-type Aβ non-fibrillar aggregates dysregulate presynaptic neurotransmission in the absence of detectable inflammation.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: March 13, 2025
Endogenously generated Dutch-type Aβ nonfibrillar aggregates dysregulate presynaptic neurotransmission in the absence of detectable inflammation.
Journal: bioRxiv : the preprint server for biology
Published: March 10, 2025
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease.
Journal: The journal of prevention of Alzheimer's disease
Published: October 28, 2024
Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice.
Journal: Molecular and cellular neurosciences
Published: April 04, 2024
Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.
Journal: Molecular and cellular neurosciences
Published: March 28, 2024
A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.
Journal: Upsala journal of medical sciences
Published: October 20, 2023
Altered amyloid-β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion.
Journal: Acta neuropathologica communications
Published: October 17, 2023
Last Updated: 09/26/2026